Specialty Pharmacy

Nilotinib (Tasigna) label includes information for patients with chronic myeloid leukemia who may stop treatment after achieving remission.

GammaPod system can accurately deliver radiation therapy to breast tumors.

Significant novel drugs slated for review by the FDA in 2018.

New research suggests that treating a common parasitic infection may reduce HIV transmission rates.

A look back at the top articles of the year on Specialty Pharmacy Times.

Top news of the week from Specialty Pharmacy Times.

Grant Knowles, PharmD, vice president, Business Development, Ardon Health, discusses the role digital health may play in patient care.

A look at the most read drug approval articles of 2017 covered by Specialty Pharmacy Times.

Cigarette smoking played a role in 19% of cancers and 29% of cancer-related deaths in 2014.

A look back at the debate around direct and indirect remuneration fees in 2017.

Enzymes that protect the immune system may malfunction and provoke cancer-related mutations.

Rinku Patel, PharmD, RPh, CEO and founder of KloudScript, discusses potential opportunities for specialty pharmacies as technology continues to evolve.

A review of the most popular video interviews on Specialty Pharmacy Times.

Pembrolizumab plus trastuzumab may overcome drug-resistance among patients with advanced HER2+ breast cancer.

Jonathan Ogurchak, PharmD, CSP, vice president of Business Operations at PANTHERx Specialty Pharmacy, discusses which drugs are expected to dominate the market in 2017.

Top news of the day from across the health care landscape.

Paclitaxel plus nintedanib overcomes chemotherapy-resistance in endometrial cancer.

Top news of the week from Specialty Pharmacy Times.

Jon Gavras, MD, chief medical officer at Prime Therapeutics, lists the strategies pharmacy benefit managers use to reduce spending on opioids.

Inhibiting a protein kinase may improve the efficacy of radiation in glioblastoma.

Significant opportunities exist for the development of new drugs for relapsing remitting multiple sclerosis.

If one-quarter of HIV-negative patients took PrEP, a significant amount of new HIV infections could be prevented.

Treatment with hydroxyurea increased hemoglobin F levels for patients with sickle cell anemia.

The FDA issued new draft guidances to expedite the approval of novel targeted drugs.

Nivolumab (Opdivo) showed better tolerability than ipilimumab (Yervoy) in patients with metastatic melanoma.

Pertuzumab (Perjeta) plus trastuzumab and chemotherapy improved invasive disease-free survival in patients with HER2+ breast cancer.

Top news of the day from across the health care landscape.

Priority areas that pharmacists should focus on ahead of USP .